

# A clinical review of first seizures in adult patients

## Abstract

First seizures in adult patients are a common problem in clinical practice, and their management represents a challenge for physicians. The aim of this review is to develop a systematic clinical approach for the classification, diagnosis and treatment of patients who have experienced a first seizure. This could help clinicians to recognize and treat this condition appropriately. Because these seizures can arise from several etiologies, it is essential to know if the event was a provoked (acute symptomatic) or unprovoked seizure. Thus, an adequate classification is important to establish the length of the diagnosis approach, the necessary treatment and every individual prognosis. We found that patients diagnosed with a single unprovoked seizure require electroencephalography and magnetic resonance imaging. This will allow an assessment of the risk of recurrence and the identification of patients that follow the diagnosis criteria for epilepsy. We recommend individualized pharmacological therapy to reduce early seizure recurrence ( $\leq 2$  years) even if it can produce some adverse effects. Finally, we determine that there are still certain areas of uncertainty to promote future research in this topic.

**Keywords:** first seizure, epilepsy, recurrence, treatment, *convulsion*

Volume 3 Issue 2 - 2019

Jose de Jesus Vidal Mayo

Internal Medicine Department, National Institute of Medical Sciences and Nutrition, Universidad Nacional Autónoma de México (UNAM), Mexico

**Correspondence:** Jose de Jesus Vidal Mayo, Internal Medicine Department, National Institute of Medical Sciences and Nutrition, Universidad Nacional Autónoma de México (UNAM), Mexico, Tel +525548158075, Email Interstrok@hotmail.com

**Received:** April 14, 2019 | **Published:** April 23, 2019

## Introduction

Seizures are a common problem in clinical practice being responsible for about 1% of hospital admissions and 3% of emergency room visits.<sup>1</sup> An epileptic seizure is a transient event of signs or symptoms due to abnormally excessive or synchronous neuronal activity in the brain.<sup>2</sup> In contrast, a *convulsion* is the motor manifestation of this abnormal neuronal activity.<sup>3</sup> A first seizure is defined as one or multiple seizures with recovery of awareness between them within a period of  $\leq 24$  hours.<sup>2</sup> Epilepsy - according the most recent definition of the International League Against Epilepsy (ILAE)- is a disease of the brain which also includes a single unprovoked seizure with a high recurrence risk over the next 10 years (at least 60%).<sup>3</sup> Therefore, it is essential to perform a correct classification of the patient's event because it establishes the management and prognosis. The aim of this review is to develop a systematic clinical approach for the classification, diagnosis and treatment of these patients to help clinicians recognize and treat this condition appropriately.

## Epidemiology

Approximately 1 of 10 people throughout their lives will present an isolated seizure.<sup>4</sup> The lifetime risk for epileptic seizures is between 8% to 10% and 2-3% chance of developing epilepsy.<sup>5,6</sup> About 40 to 50% of the first seizures correspond to provoked (acute symptomatic) seizures.<sup>7,8</sup> The incidence regarding first seizures in Europe is around 70 per 100,000 inhabitants per year and is twice as common in the worldwide poorest countries.<sup>9</sup> In the United States of America (USA) close to 150,000 people present a first unprovoked seizure annually.<sup>10</sup> Some studies have reported a bimodal pattern of presentation with a higher incidence for children  $< 1$  year of age (252.9 per 100,000 per year) and for adults  $> 75$  years (173.2 per 100,000 per year).<sup>11</sup> There are no epidemiological data in the Mexican population regarding this entity. However, according to the epilepsy priority program there are about 2 million people with epilepsy in our country.<sup>12</sup>

## Classification

For this review, we classify the epileptic seizures in two large groups:

**Acute symptomatic seizures** (also called *provoked seizures*): They are in close temporal association with an acute damage to the central nervous system which may be of metabolic, toxic, structural, infectious or inflammatory origin.<sup>13</sup> They are presumably the acute manifestation of the insult.<sup>14</sup> The temporal relationship in this definition is within the first week in stroke, head trauma or anoxic encephalopathy. The active phase of the infections in the central nervous system (based on persistent clinical, laboratorial or imaging findings) is not beyond 24 hours for severe metabolic derangement and between 7 to 48 hours since the last alcohol intake in alcohol withdrawal.<sup>13</sup>

**Unprovoked seizures** (also called *remote symptomatic seizures*): They occur in the absence of a precipitating factor and may be conditioned by a static or progressive injury.<sup>14</sup> These ones are the kind of seizures closely related to epilepsy.<sup>15</sup> Seizures can also be classified according to their presumed clinical and electrographic patterns, as generalized (they arise and engage neural networks in both cerebral hemispheres), or focal (they engage neural networks only in one cerebral hemisphere).<sup>16</sup> Other experts have suggested a different classification for this topic,<sup>17</sup> but we prefer to divide first-time seizures in provoked and unprovoked seizures to avoid confusion with the nomenclature.

## Etiology

Causes of *acute symptomatic seizures* can be categorized as follows:<sup>15,18,19</sup>

## Neurologic insults

I. Traumatic brain injury (TBI), brain surgeries are included in this section. Some factors associated with seizure occurrence in this

context are: age (more common in children), loss of awareness, amnesia for >30 minutes, and the presence of cerebral hemorrhages or subdural hematomas.<sup>20</sup>

- II. CNS infections: about 5% of the patients will have seizures during the acute phase.<sup>21</sup> The risk factors described are: encephalitis (14 times more frequently compared to meningitis), the etiological agent (most common in herpes simplex encephalitis - up to 40% to 60% of cases -), age >42 years and ≤12 in the Glasgow coma scale (GCS) score at admission.<sup>18,22</sup>
- III. Acute stroke: those patients with cerebral vein thrombosis present more frequently symptomatic seizures (up to 39% of cases),<sup>23</sup> followed by those ones with subarachnoid hemorrhage (6 to 18% of patients),<sup>24</sup> up to 16% of cases in intracerebral hemorrhage,<sup>25</sup> and finally patients who have experienced ischemic stroke (4 to 9%).<sup>26-28</sup>

**Metabolic disorders**

Metabolic disorders are responsible for 2.9 to 5% of epileptic seizures in emergency departments.<sup>29,30</sup> In this group we can include sodium, calcium and magnesium derangements as well as glucose disorders, and the settings of acute liver failure, uremic syndrome and thyroid emergencies. If there are electrolytic disturbances, the probability for the development of seizures depends on the speed and severity of instauration.<sup>18,19</sup> In glucose disorders, seizures occur more frequently in the context of hyperglycemic crises (up to 25%) -particularly in the hyperglycemic hyperosmolar state, probably due to the antiepileptic effect of ketosis<sup>19</sup> compared to hypoglycemia (7% of cases of severe hypoglycemia).<sup>31</sup> The associated alterations and their respective cut-off points related to seizures are represented in the Table 1.<sup>13,15,19</sup>

**Table 1** Metabolic disorders and their respective cut-off related to seizures

Sodium	Hyponatremia <115 mmol/L
Calcium	Hypocalcemia <5 mg/dl
Magnesium	Hypomagnesemia <0.8 mg/dl
Glucose	Hypoglycemia <36 mg/dl
	Hyperglycemia ≥400-450 mg/dl

**Medications**

Around 6% of first-time seizures are produced by pharmacological toxicity.<sup>32</sup> There are more than 250 drugs related to seizures with an adverse effect.<sup>33</sup> This association can occur either in their therapeutic use (very rare, only 0.08%<sup>34</sup>) and in overdosing.<sup>19</sup> Some drugs with an elevated risk for seizures are isoniazid, bupropion and venlafaxine.<sup>35</sup> Table 2 lists the most representative drugs.<sup>19,35 36</sup> Evidence for an association between antibiotics and symptomatic seizures is low to very low. Most of reports involve unsubstituted penicillins, fourth-generation cephalosporins, imipenem and ciprofloxacin in combination with renal dysfunction, brain lesions, and epilepsy.

<sup>37</sup>Frequency of 0.9% in a large series of critical ill patients

<sup>19</sup>From doses ≥20 mg/kg

<sup>38</sup>Most common in first 2 days of therapy and with high doses in renal dysfunction

<sup>39</sup>Risk with therapeutic doses up 0.4-2%

<sup>40</sup>Up to 2.2% with doses >450 mg/day and with <450 mg/day until 0.4% of patients

<sup>34</sup>It is related to seizures with levels higher than 3 mEq/L.

**Table 2** Common medications associated with acute symptomatic seizures

Drug class	Representative medications
Antibiotics <sup>36</sup>	Beta lactams: penicillins and cephalosporins.  Carbapenems: imipenem-cilastatin, <sup>37</sup> meropenem and doripenem.  Fluoroquinolones.  Isoniazid. <sup>19</sup>
Antivirals	Aciclovir <sup>19,38</sup>
Metilxantins	Theophyline
Antidepressants	Tricyclic antidepressants. <sup>39</sup>  Selective serotonin reuptake inhibitors.  Bupropion. <sup>40</sup>  Venlafaxin.
Antipsychotics	First generation: chlorpromazine (the highest risk), molindone, haloperidol, fluphenazine, pimozide and trifluoperazine. Second generation: clozapine.  Lithium. <sup>34</sup>
Narcotics	Meperidine, morphine and propoxyphene.
Antiepileptic drugs	Carbamazepine, phenytoin.
Anticholinergic drugs	Dyphenhydramine.
Sodium channel blockers	Lidocaine.

**Alcohol and toxics**

Alcohol abuse is associated from 20 to 40% of patients with seizures in emergency departments. Although alcohol abstinence is the most common setting, we must consider all the other possibilities that can produce first seizures in these patients.<sup>35</sup> Regarding substances of abuse, the most evident associations are abstinence from hypnotic-sedative drugs (benzodiazepines and barbiturates) and intoxication by sympathomimetics (cocaine and amphetamines).<sup>18,35</sup> Other substances with uncommon association are heroin, mescaline, psilocybin, psilocin and synthetic ergotamine derivatives of diethylamide D-lysergic acid (LSD).<sup>18</sup>

**Others**

The seizures associated with posterior reversible encephalopathy syndrome (PRES) and eclampsia are considered within this group.<sup>18,19</sup> About the etiology of *unprovoked seizures*, the most recent ILAE's classification suggests the following categories: genetic, structural, infectious, metabolic, immune and unknown (Table 3).<sup>41 42</sup> It is the most common cause of epilepsy in Mexican adults.

Some common etiologies should be considered according to the age group of the patient:<sup>18</sup>

- I. 15-34 years: traumatic brain injury, medications, alcohol-toxics and eclampsia

- II. 35-64 years: brain tumors: primary - more frequent in low-grade tumors - or metastatic tumors<sup>43,44</sup>
- III. 65 years: cerebrovascular diseases are the main etiology (overall 50%) followed by traumatic brain injury and brain tumors.<sup>38</sup>

Some large series found as main causes of seizures in emergency departments the consumption of alcohol or toxics (19%), TBI (7.8%-16%), cerebrovascular diseases (16%) and infections (15%).<sup>29,46</sup> The contribution of epilepsy in one of these studies was 6.8% and up to 41% of the seizures were classified as unknown.<sup>29</sup> In approximately 45% of patients with first-time seizures in emergency departments no cause is identified, and they are produced in <10% by toxic-metabolic etiologies.<sup>47</sup>

**Table 3** Main etiologies of unprovoked seizures and epilepsy

Etiology	Representative clinical conditions
Structural	Stroke, TBI, tumors, infection.
Genetic	Juvenil Myoclonic Epilepsy
Infectious	Neurocysticercosis, <sup>42</sup> tuberculosis, HIV, cerebral toxoplasmosis, cerebral malaria, postinfectious epilepsy.
Metabolic	Porphyria, aminoacidopathies or pyridoxine-dependent seizures.
Immune	Autoimmune encephalitis
Unknown	Frontal lobe epilepsy.

### Clinical features

Spectrum of clinical presentation depends of the underlying neuroanatomy, and can range from a focal motor crisis without altered awareness to generalized tonic-clonic seizures leading to a convulsive status epilepticus.<sup>14,48</sup> The predominant one is as generalized seizures (86%).<sup>29</sup> Most of etiologies of acute symptomatic seizures (especially toxic-metabolic causes) produce generalized tonic-clonic seizures.<sup>16</sup> For epidemiological purposes, multiple seizures within 24 hours (seizure clusters) and first status epilepticus are considered as a first epileptic seizure since in themselves these events do not establish the diagnosis of epilepsy.<sup>9,17,49</sup> A study by Kho et al.<sup>49</sup> found no difference in the rate of recurrence between patients who experienced seizure clusters versus patients with a single seizure, regardless of etiology or treatment.<sup>50</sup>

### Diagnostic approach

We suggest a systematic approach based on the following sequence:<sup>51,52</sup>

- I. Define if the patient's event really corresponds to an epileptic seizure
- II. Establish the etiology and classify the event: provoked versus unprovoked seizure
- III. Identify if the event is about the first seizure or there have been previous events

IV. Complementary studies (laboratory, brain imaging and electroencephalogram)

V. Categorize - if possible - the type of epileptic seizure, epilepsy and/or epileptic syndrome

VI. Estimate the risk of seizure recurrence

VII. Define the need for treatment with antiepileptic drugs (AED).

### History and physical examination

The initial clinical assessment should include a complete clinical history with emphasis on the family history as well as a physical examination directed towards the evaluation of vital signs, look for any neurological deficit, and the search of potential acute etiologies of the episode. Diagnosis of epileptic seizures and epilepsy are eminently clinical, thus it is essential perform an adequate semiology of the event, so the description of the episode by the patient (if possible) or by a visual witness is of utmost relevance.<sup>48,53</sup> Also, it is recommended an early evaluation by the neurologist when this entity is suspected or if there is doubt about the diagnosis.<sup>9,51,54</sup>

The first step is to determine if we are facing a first epileptic seizure or corresponds to another spell, because an inadequate diagnosis is made between 16-42% of the cases.<sup>55</sup> Syncope and psychogenic non-epileptic seizures (PNES) are the main differential diagnoses.<sup>11,51,54,55</sup> In the Table 4 are showed the main differential diagnoses of seizures in clinical practice.<sup>47,54</sup> Some clinical features that suggest that the event is an epileptic seizure are postictal confusion, cyanosis, lateral tongue biting, preceding *déjà vu* or *jamais vu*, confirmed unresponsiveness, head or gaze turning to one side, and the presence of limb rhythmic shaking or tonic posturing.<sup>9</sup>

I. Syncope: It is a more frequent situation in the general population, especially the vasovagal. This diagnosis is supported by the presence of a situational factor and prodromal symptoms such as blurred vision, sweating, dizziness, nausea, dyspnea or palpitations and paleness. There may be associated myoclonic movements and even generalized tonic-clonic seizures during the episode due to cerebral hypoxia when the patients cannot adopt the supine position.<sup>9,48</sup>

II. Psychogenic non-epileptic seizures (PNES): These spells are characterized by behaviors closely resembling seizures with a psychiatric background, but they do not have the clinical and electrographic findings present during an epileptic seizure. They are frequent, accounting for up to 12-18% of paroxysmal events with transient loss of awareness and 30 to 50% of patients admitted to electroencephalographic monitoring units.<sup>9,48</sup> Some features that suggest this entity are prolonged duration of apparent loss of awareness with normal colour and/or oxygen saturation on room air, fluctuating motor activity, asynchronous movements with non-anatomical dissemination, side-to-side head or body movements, pelvic thrusting, ictal crying, presence of closed eyes during the event with resistance to its opening, and a rapid postictal recovery.<sup>9,48,54</sup>

About the second point of the approach sequence, we must rule out a provoked seizure in all patients who have experienced a first-time seizure, and only after that, we can label the seizure as unprovoked.<sup>14,15</sup> Regarding the third point of the sequence, it is reported that between 7 to 50% of the patients who present for evaluation of a first seizure have experienced previous seizures, and that these ones are absences, focal

or myoclonic seizures generally.<sup>11,51</sup> This fact is essential because it determines if the patient meets diagnostic criteria for epilepsy, which has a different treatment and prognosis than a single first seizure.

**Table 4** Most important seizures mimickers in clinical practice

Non-neurologic differential diagnosis	Neurologic differential diagnosis
Syncope	Cerebrovascular disorder –transient ischemic attacks (TIAs)
Delirium	Episodic movement disorders
Metabolic encephalopathies	Migraine
	Sleep disorders: cataplexy, parasomnia, REM behavior disorder, periodic limb movements during sleep.
	Psychogenic non-epileptic seizures (PNES)
	Vestibulopathy
	Transient global amnesia
	Panic attacks

### General laboratory studies (blood cytometry, glucose, serum electrolytes)

From 0 to 15% of the patients present alterations in these studies, but they have clinical significance rarely (<5%).<sup>55,56</sup> Thus, they should be requested in an individualized way without use them routinely.<sup>55–57</sup> However, we suggest to assess serum glucose as well as serum electrolytes (sodium, calcium and magnesium) in every patient who has experienced a first seizure.

### Electroencephalography

Electroencephalogram (EEG) must be performed in all patients who have experienced a first unprovoked seizure and shows significant abnormalities in 29% of these patients.<sup>57</sup> In addition, it helps to classify the seizure type (epileptic vs non-epileptic, focal vs generalized), to identify the seizure focus involved, and to characterize the seizure subtype. Therefore, EEG have implication to define the risk of recurrence and the treatment which could be employed in each patient.<sup>48,55,57,58</sup> The sensitivity of a single routine record for epileptiform discharges is <50% in patients with epilepsy.<sup>48</sup> However, the diagnostic yield can increase by performing 3 or more serial records (up to 80-90%), performing records within first 24 hours after the epileptic seizure, and with stimulation maneuvers such as hyperventilation, photostimulation and sleep deprivation (up to 80%).<sup>9,48,57</sup> Some paroxysmal discharges with high epileptogenic potential (>90%) are the anterior temporal lobe spikes, vertex spikes, generalized paroxysmal fast activity, generalized slow spike and wave and hypersarrhythmia.<sup>48</sup> Probability of seizure recurrence is estimated around 77% when there are epileptiform discharges.<sup>59</sup> Recent studies of patients who had experienced first-time unprovoked seizures in emergency departments found a higher diagnostic yield if the EEG was performed before their discharge (24% and 29.4% of them had abnormal records), which was relevant for starting AED treatment as well as the epilepsy diagnosis.<sup>60,61</sup> A study by Chen et al.<sup>61</sup> 24 hours video-electroencephalography was performed within the first

7 days in patients who had first unprovoked seizures; epileptiform abnormalities were found in nearly 42% of them and were a risk factor for seizure recurrence (RR 2.25, CI 95% 1.30-3.92).<sup>62</sup> Among its main limitations are that it does not exclude the diagnosis of epilepsy, the lack of its availability in emergency departments, its cost and the misinterpretations of the records.<sup>48,55</sup>

### Brain imaging

A neuroimaging study (CT or MRI) must be performed in all patients with unprovoked first-time seizures.<sup>57</sup> Cranial tomography (CT) scan shows significant alterations in approximately 10% of patients with this condition.<sup>57</sup> It is considered the first line imaging modality due to its wide availability in emergency departments and allows a faster diagnostic evaluation in patients who present an acute neurological deficit; especially, to exclude vascular etiologies or any situation that warrants neurosurgical treatment. Hence, CT scan must perform in every patient who has experienced a first seizure.<sup>9,47,51,63</sup> Magnetic resonance imaging (MRI) is warranted in all patients with a first unprovoked seizure; unless, they have contraindications for its realization.<sup>48,57</sup> MRI is more sensitive than CT scan because allows a greater identification of significant lesions such as intraparenchymal hemorrhages, brain tumors, vascular malformations, posttraumatic changes, mesial temporal sclerosis, and malformations of cortical development.<sup>48</sup> Studies in this setting have reported that close to 30% of the patients was found a potentially epileptogenic alteration,<sup>63,64</sup> and of these patients about 12% had some specific pathological finding in presence of a normal CT.<sup>63</sup> The diagnostic yield of MRI is higher in patients with a first focal or provoked seizure (around 50%), and performing an epilepsy protocol-specific brain MRI.<sup>65,66</sup>

### Lumbar puncture

This procedure should be considered in patients with clinical suspicion of CNS infection, subarachnoid hemorrhage as well as in those with persistent impairment in mental status or are immunocompromised (even if they are afebrile).<sup>47,67</sup> Some abnormalities in the cerebrospinal fluid of patients who experienced a first unprovoked seizure are hyperproteinorrachia (30%) followed by pleocytosis (10% of the cases, mean of 10.2 cells/mm<sup>3</sup>). They are probably due to a transient disruption of the blood-brain barrier after the seizure.<sup>68</sup>

### Other tests: toxicological profile, prolactin levels, electrocardiogram and pregnancy test

Toxicological profile may be performed in selected cases where there is high clinical suspicion as in patients who have a toxidrome, known consumption of substances or altered mental status on examination. Nonetheless, there is not enough evidence to perform it routinely.<sup>56–58</sup> Prolactin levels have been measured above their normal value in patients who experienced an epileptic seizure and have been used to discriminate between seizures with altered awareness from psychogenic non-epileptic seizures (PNES). The above is applicable if there is a baseline determination of them (6 hours prior to the event), and these ones are compared against a new determination performed 10-20 minutes after the episode, which is complicated to implement in clinical practice. Besides, they cannot distinguish seizures from syncope because in both situations they can be elevated.<sup>69</sup> Other studies which should be performed in all patients in this setting are 12-lead electrocardiogram and pregnancy test in childbearing age women. The first one to look for any cardiac disturbance related to

syncope, and the second one due to the association with eclampsia and pregnancy itself with epilepsy.<sup>9,51</sup> Depending on the context of each patient, it may be considered to request a test for detection of human immunodeficiency virus (HIV), Holter study, echocardiogram, etcetera.<sup>51,70</sup> Summary of tests which we must perform in adult patients who have experienced a first seizure are shown in the Box 1. Box 1 Emergency tests to perform in all patients who have experienced a first seizure

---

#### All patients (Emergency department assessment)

---

- Serum glucose
  - Serum electrolytes: sodium, calcium and magnesium.
  - 12 leads electrocardiogram
  - Neuroimaging study: CT scan.<sup>1</sup>
- Patients with a first unprovoked seizure
- Electroencephalogram.
  - Magnetic resonance imaging.<sup>2</sup>
- 

It is preferred by a greater speed and availability in E.D.

Perform epilepsy-protocol specific MRI if it is available.

### Risk of seizure recurrence

#### Acute symptomatic seizures

Patients with seizures resulting from acute brain insults (severe closed injury, acute hemorrhagic and ischemic stroke, brain surgery and CNS infections in active phase) have a lower recurrence rate (risk of seizure recurrence from 10 to 20%) compared to those with remote symptomatic seizures.<sup>14,17</sup> A study by Hesdorffer *et al.* found that the risk of recurrence for a second seizure in patients who were diagnosed with stroke, TBI and CNS infections was significantly greater only for remote symptomatic seizures when these ones were compared against acute symptomatic seizures in the same setting; demonstrating that, in general, remote symptomatic seizures had a risk of recurrence greater than 60%.<sup>71</sup>

#### Unprovoked seizures

Global risk of recurrence for a second seizure after a first unprovoked seizure is by 21-45% within the first two years,<sup>72</sup> and is particularly higher in the first 6 months (60-70% of recurrences).<sup>51,73</sup> The likelihood of recurrence after the second seizure increases to 57% at 1 year, and 73% at 4 years; besides, it is associated with a proportional increase in the frequency of episodes as well as a concomitant reduction in the free interval between subsequent seizures.<sup>74</sup> Patients at increased risk for seizure recurrence after a first unprovoked seizure according the American Academy of Neurology (AAN) Guideline Analysis are the following:<sup>72</sup>

I. Patients with prior brain lesion or insult (remote symptomatic). This group includes the seizures arising from stroke, traumatic brain injury, CNS infections, cerebral palsy and cognitive developmental disability. (Level A of evidence)

II. EEG with epileptiform abnormalities (Level A of evidence)

III. Significant brain-imaging abnormality (Level B of evidence)

IV. Nocturnal seizure (Level B of evidence).

Although there is no precise formula to estimate the risk of seizure recurrence in each patient, according to the model of Kim *et al.*<sup>22</sup> patients with history of an abnormal neurological status plus an abnormal electroencephalogram have a risk of recurrence greater than 60% at 3 and 5 years.<sup>75</sup> However, this tool have several limitations such as it does not consider the brain imaging, and it has not been validated in other studies.<sup>17,72,75</sup>

### Treatment with antiepileptic Drugs

The evidence regarding pharmacological treatment in this clinical entity and the ILAE's definition of epilepsy involves only *unprovoked seizures*. Thus, the treatment of *provoked seizures* corresponds to the specific of each underlying condition, and the use of antiepileptic drugs is to prevent further acute symptomatic seizures.<sup>15,18</sup>

Starting antiepileptic drug therapy in patients who have experienced a first unprovoked seizure reduces the risk for a second seizure by about 35% within the subsequent 2 years;<sup>72</sup> however, it has no impact on long-term recurrence ( $\geq 3$  years after the first episode) and has not demonstrated any improvement in patients' quality of life.<sup>72,76</sup> In addition, pharmacological treatment can produce adverse effects (7-31% of cases), although these ones are generally mild and reversible.<sup>72</sup> The evidence about efficacy of AED in the reduction of seizure recurrence arises from several randomized trials, but the main ones are: The First Seizure Trial Group study (FIR.ST)<sup>77</sup> and the European Multicenter Epilepsy and Single Seizure Study (MESS).<sup>78</sup> In both trials it was found that the risk of seizure recurrence at 2 years was 50% less in the group of patients who had immediate AED therapy (adjusted relative risk 0.5; CI 95% = 0.3-0.6), but there was no impact on long-term remission rate of these patients.<sup>52,77,78</sup> The only controlled, randomized and double blind trial by Chandra *et al.*<sup>79</sup> found a difference close to 52% between the group of patients who were treated with valproic acid after a first unprovoked seizure vs. the untreated group (4.3% in the treated group vs. 55.7% in the placebo group); nevertheless, it did not assess the clinical remission.<sup>79</sup> Others two smaller trials found differences of seizure recurrence by 34% and 49% between patients who were treated with AEDs and untreated patients after a single unprovoked seizure.<sup>80,81</sup> A meta-analysis of six studies in this setting showed an absolute risk reduction for seizure recurrence by 34% (CI 95% 15-52%).<sup>56</sup> Some important factors to consider prior to begin AED therapy are the following:<sup>14,15,17</sup>

I. Etiology and risk of seizure recurrence

II. Seizure and epilepsy type

III. Patient's age

IV. Patient's comorbidities: pregnancy, kidney or hepatic failure, etc

V. Pharmacological properties of AED: pharmacokinetic and pharmacodynamic features, pharmacological interactions, individual tolerance, side effects, cost and availability

VI. Inpatient vs. outpatient treatment. Some indications for hospital admission are shown in the Box 2.

Box 2 indications for hospital admission in the setting of patients with first seizures<sup>9,51</sup>

- Age >60 years
- Underlying etiology requiring urgent treatment (TBI, stroke, CNS infections, intoxications, etc.)
- Abnormal level of awareness.
- Presence of neurological deficit.
- Recurrent or persistent seizures.
- Comorbidities (immunosuppression, cancer, established cardiovascular disease).
- Inadequate social support for discharge.

Therefore, the decision about starting antiepileptic drug therapy must be individualized and should be always made in conjunction with patients.<sup>72,82</sup> We need to consider specific medical, social and employ features of each patient; although, the final decision corresponds to the specialist in this field (neurologist, epileptologist).<sup>9,17,55,58,71</sup> In the Table 5 we provide a guide about the specific drugs to use according the seizure type in adults and in older patients (>60 years).<sup>14,58,83</sup>

**Table 5** Preferred antiepileptic drugs according to the type of seizure

Seizure type	First line antiepileptic drugs
Generalized tonic-clonic	Carbamazepine
	Lamotrigine
	Oxcarbazepine
	Sodium valproate
	Levetiracetam
	Topiramate
Focal	Carbamazepine
	Levetiracetam
	Oxcarbazepine
	Sodium valproate
	Phenytoin
	Zonisamide
Abscenses	Ethosuximide
	Sodium valproate
	Lamotrigine
Myoclonic	Levetiracetam
	Sodium valproate
	Topiramate
Focal seizures in older patients	Lamotrigine
	Gabapentine
	Levetiracetam <sup>84,85</sup>

### Length of therapy

Around 70% of patients with new-onset epilepsy enter prolonged seizure remission during treatment with AED.<sup>86</sup> In patients with epilepsy, the factors associated with successful remission after starting AED therapy are a seizure free interval for more than 2 years and a normal neurological examination.<sup>87</sup> On the other hand, risk factors related to seizure recurrence after withdrawal are age  $\geq 16$  years, need for more than one AED, seizures during AED therapy, history of generalized tonic-clonic or myoclonic seizures, and an abnormal EEG in prior year.<sup>88</sup> The largest trial about withdrawal of AEDs in patients with epilepsy who had been seizure-free for at least 2 years showed that 59% of them remained seizure-free at 2 years after weaning the medications. Also, it found that AED discontinuation doubles the risk of seizures for up to 2 years after stopping AED compared to continued treatment.<sup>89</sup> Consequently, it is recommended consider withdrawal AED therapy in those patients who have been seizure-free for at least 2 years and without high individual risk of seizure recurrence.<sup>90</sup> Patients with provoked seizures due to their low risk for developing epilepsy, the prophylaxis could be limited to 7 days (e.g. metabolic disorders), and from 1 to 6 months in patients with an acute brain insult.<sup>14</sup>

### Follow up and prognosis

It is suggested to perform a second evaluation by a neurologist within the first 4 weeks after the event in patients who experienced a first unprovoked seizure and those with suspected epilepsy, to complete the diagnostic tests (electroencephalogram and magnetic resonance imaging) as well as to define the need of AED therapy.<sup>91</sup> The use of specialized clinics in the evaluation of patients with first-time seizures allows a faster implementation of their study protocol and a faster diagnosis, with approximately 40% of patients evaluated in these centers meeting diagnostic criteria for epilepsy.<sup>92</sup> Some general recommendations for these patients are avoid the known precipitants of the seizures (if any) as well as the consumption of alcohol and other drugs which reduce the epileptic threshold, consider driving accompanied because them have increased risk of traffic accidents (up to 40% more), and avoiding high risk activities (water sports, heavy machinery use, etc.) for at least 3-6 months with even larger periods for patients who have experienced unprovoked seizures.<sup>9,51,93</sup> Standardized mortality ratio (SMR) after a first unprovoked seizure is 2.3, which is within the reported SMR by 2 to 4 for patients with epilepsy.<sup>10,94,95</sup> Mortality of symptomatic seizures is high, ranging from 10% to 40%; however, it is difficult to distinguish between seizure-related deaths from deaths attributable to the underlying etiology.<sup>36</sup>

### Discussion

First seizures in adult patients are clinical significant events which require a systematic - multidisciplinary approach to identify those patients with a potential acute etiology, and separate them from those with unprovoked seizures and new onset epilepsy. The randomized trials and meta-analysis have found that the antiepileptic drugs do not reduce the risk for a second unprovoked seizure beyond the first two years since the first event; however, a seizure can be a terrifying event with medical and social consequences. Thus, the decision about starting pharmacological therapy should be individualized based in several factors mentioned previously. This review summarizes the most recent scientific evidence in this field, and provides a practical framework for a suitable classification, diagnosis and treatment of these patients as well as some elements to consider in the patient counseling

after a first seizure. There are several areas of uncertainty in this topic that are potential fields for future research. For example; some experts have questioned when a first unprovoked seizure is epilepsy; although, most of experts consider with the diagnosis of epilepsy those patients who have epileptiform abnormalities on EEG or a significant etiology in MRI. A prospective study by Lawn et al reported that after the first seizure, a freedom seizure interval of 12 weeks reduced the initial risk of seizure recurrence of those patients (all of them had a basal risk of recurrence greater than 60% at 10 years); in other words, that the risk of seizure recurrence was time-dependent.<sup>96</sup> Also, the length of therapy in patients who have experienced a single seizure is uncertain because the available evidence concerning weaning AEDs arises from patients with epilepsy. Besides, it is necessary assess the effectiveness and the frequency of side effects of the new antiepileptic drugs because most of trials in this setting used older AEDs. Likewise, the effects at the epidemiological level regarding the diagnosis of epilepsy as well as the socioeconomic, legal and emotional consequences in patients receiving antiepileptic drug therapy are unknown.<sup>55,71</sup> Finally, it is important to evaluate the performance of the first seizure centers in other populations, and meet the challenges that they are facing in the management of these patients such as poor diagnostic accuracy of the referring doctors, under-detection of previous seizures, inadequate classification of seizures and low yield of investigations.<sup>97</sup>

## Conclusion

First seizures in adults are common in clinical practice. A systematic approach will help clinicians to classify the patients appropriately between those with provoked seizures and unprovoked seizures as well as those who meet diagnostic criteria for new-onset epilepsy, because the management and prognosis of each condition is very different. We must rule out a provoked seizure in all patients who have experienced a first seizure because they have a higher mortality and their treatment is defined by the underlying etiology. Patients who have experienced unprovoked seizures need to perform an EEG and a brain MRI to estimate the risk of seizure recurrence. Antiepileptic drug therapy must be individualized, without forgetting that only impacts in the early seizure recurrence (first 2 years) and may produce side effects. Every patient needs a tight follow-up, especially those who have experienced a first unprovoked seizure to complete their study protocol and to define the need of antiepileptic drug therapy.

## Acknowledgments

None.

## Conflicts of interest

The author declares there is no conflict of interest.

## References

1. All Party Parliamentary Group on Epilepsy: *Wasted money, wasted lives: the human and economic cost of epilepsy in England*. Stationery Office. 2007.
2. Fisher RS, van Emde Boas W, Brune W, et al. Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the international Bureau for Epilepsy (IBE). *Epilepsia*. 2005;46(4):470–472.
3. Fisher RS, Acevedo C, Arzimanoglou A, et al. ILAE official report: A practical clinical definition of epilepsy. *Epilepsia*. 2014; 55(4):475–482.
4. Hauser WA, Annegers JF, Kurland LT. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935–1984. *Epilepsia*. 1993;34(3):453–468.
5. Hauser WA, Annegers JF, Rocca WA. Descriptive epidemiology of epilepsy: contributions of population-based studies from Rochester, Minnesota. *Mayo Clin Proc*. 1996;71(6):576–586.
6. Berg AT, Shinnar S. The risk of seizure recurrence following a first unprovoked seizure. *Neurology*. 1991;41(7):965–972.
7. Loiseau J, Loiseau P, Guyton M, et al. Survey of seizure disorders in the French southwest: I. Incidence of epileptic syndromes. *Epilepsia*. 1990;31(4):391–396.
8. Rizvi S, Ladino LD, Hernandez-Ronquillo L, et al. Epidemiology of early stages of epilepsy: Risk of seizure recurrence after a first seizure. *Seizure*. 2017;49:46–53.
9. Angus Leppan H. First seizures in adults. *BMJ*. 2014;348:g2470.
10. Hauser WA, Beghi E. First seizure definitions and world-wide incidence and mortality. *Epilepsia*. 2008;49(Suppl 1):8–12.
11. Martindale MD, Goldstein JN, Pallin DJ. Emergency Department Seizure Epidemiology. *Emerg Med Clin N Am*. 2011;29(1):15–27.
12. México, programa prioritario de epilepsia. 2017.
13. Beghi E, Carpio A, Forsgren L, et al. Recommendation for a definition of acute symptomatic seizure. *Epilepsia*. 2010;51(4):671–675.
14. Gavvala JR, Schuele SU. New-Onset Seizure in Adults and Adolescents: A Review. *JAMA*. 2016;316(24):2657–2668.
15. Espinosa-Jovel CA, Sobrino-Mejía FE. Clinical approach to the first epileptic crisis in adults. *Rev Neurol*. 2014;58(8):365–374.
16. Berg AT, Berkovic SF, Brodie MJ, et al. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005–2009. *Epilepsia*. 2010;51(4):676–685.
17. Bergey GK. Management of a First Seizure. *Continuum (Minneapolis)*. 2016;22(1):38–50.
18. Beleza P. Acute Symptomatic Seizures: A Clinically Oriented Review. *The Neurologist*. 2012;18(3):109–119.
19. Karceski S. Acute Symptomatic Seizures and Systemic Illness. *Continuum (Minneapolis)*. 2014;20(3):614–623.
20. Burns J Jr, Hauser WA. The epidemiology of traumatic brain injury: a review. *Epilepsia*. 2003;44(Suppl 10):2–10.
21. Ziai WC, Lewin JJ. Update in the diagnosis and management of central nervous system infections. *Neurol Clin*. 2008;26(2):47–468.
22. Kim MA, Park KM, Kim SE, et al. Acute symptomatic seizures in CNS infection. *Eur J Neurol*. 2008;15(1):38–41.
23. Ferro JM, Canhao P, Boussier MG. Early seizures in cerebral vein and dural sinus thrombosis: risk factors and role of antiepileptics. *Stroke*. 2008;39(4):1152–1158.
24. Conolly ES, Rabinstein AA, Carhuapoma JR, et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke*. 2012;43(6):1711–1713.
25. Hemphill JC 3<sup>rd</sup>, Greenberg SM, Anderson CS, et al. Guidelines for the Management of Spontaneous Intracerebral Hemorrhage: A Guideline for Healthcare Professionals from the American Heart Association/American Stroke Association. *Stroke*. 2015;46(7):2032–2060.

26. Giroud M, Gras P, Fayolle H, et al. Early seizures after acute stroke: a study of 1,640 cases. *Epilepsia*. 1994;35(5):959–964.
27. Sung CY, Chu NS. Epileptic seizures in thrombotic stroke. *J Neurol*. 1990;237(3):166–170.
28. Bladin CF, Alexandrov AV, Bellavance A, et al. Seizures after stroke: a prospective multicenter study. *Arch Neurol*. 2000;57(11):1617–1622.
29. Ong S, Talan DA, Moran GJ, et al. Neurocysticercosis in radiographically imaged seizure patients in U.S. emergency departments. *Emerg Infect Dis*. 2002;8(6):608–613.
30. Hennem PL, DeRoos F, Lewis RJ. Determining the need for admission in patients with new onset seizures. *Ann Emerg Med*. 1994;24(6):1108–1114.
31. Gutierrez A, Riggs JE. *Seizures and electrolyte imbalance*. In: Delanty N editor. *Seizures: medical causes and management*. Totowa: Humana Press Inc. 2002. p. 85–106.
32. Chen HY, Albertson TE, Olson KR. Treatment of drug-induced seizures. *Br J Clin Pharmacol*. 2015;81(3):412–419.
33. Physicians Desk Reference. 2014. Montvale, NJ. *PDR Network*, 2014.
34. García PA, Alldregue BK. *Medication-induced seizures*. In: Delanty N editor. *Seizures: medical causes and management*. Totowa: Humana Press Inc, 2002. p. 147–165.
35. Sharma AN, Hoffman RJ. Toxin Related Seizures. *Emerg Med Clin N Am*. 2011;29:125–139.
36. Sutter R, Rüegg S, Tschudin-Sutter S. Seizures as adverse events of antibiotic drugs: A systematic review. *Neurology*. 2015;85(15):1332–1341.
37. Calandra G, Lydick E, Carrigan J, et al. Factors predisposing to seizures in seriously ill affected patients receiving antibiotics: experience with imipenem/cilastatin. *Am J Med*. 1988;84(5):911–918.
38. Martínez GJ, Hsia R. Altered mental status from acyclovir. *J Emerg Med*. 2011;41(1):55–58.
39. Montgomery SA. Antidepressants and seizures: emphasis on newer agents and clinical implications. *Int J Clin Pract*. 2005;59(12):1435–1440.
40. Davidson J. Seizures and bupropion: a review. *J Clin Psychiatry*. 1989;50(7):256–261.
41. Scheffer IE, Berkovic S, Capovilla G, et al. ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology. *Epilepsia*. 2017;58(4):512–521.
42. Medina MT, Rosas E, Rubio-Donnadieu F, et al. Neurocysticercosis as the main cause of the late-onset epilepsy in Mexico. *Arch Intern Med*. 1990;150(2):325–327.
43. Van Breemen MS, Wilms EB, Vecht CJ. Epilepsy in patients with brain tumours: epidemiology, mechanisms and management. *Lancet Neurol*. 2007;6(5):421–430.
44. Ertük Cetin Ö, Isler C, Uzan M, et al. Epilepsy-related brain tumors. *Seizure*. 2017;44:93–97.
45. Liu S, Yu W, Lu Y. The causes of new onset epilepsy and seizures in the elderly. *Neuropsychiatric Disease and Treatment*. 2016;12:1425–1434.
46. Annegers JF, Hauser WA, Lee JR, et al. Incidence of acute symptomatic seizures in Rochester, Minnesota, 1935–1984. *Epilepsia*. 1995;36(4):327–33.
47. Jagoda A, Gupta K. The Emergency Department Evaluation of the Adult Patient Who Presents with a First-Time Seizure. *Emerg Med Clin N Am*. 2011;29(1):41–49.
48. St. Louis E, Cascino GD. Diagnosis of Epilepsy and Related Episodic Disorders. *Continuum (Minneapolis)*. 2016;22(1):15–37.
49. Guidelines for epidemiologic studies on epilepsy. Commission on Epidemiology and Prognosis, International League against Epilepsy. *Epilepsia*. 1993;34(4):592–596.
50. Kho LK, Lawn ND, Dunne JW, et al. First seizure presentation: do multiple seizures on 24 hours predict recurrence? *Neurology*. 2006;67(6):1047–1049.
51. Seneviratne U. Management of the first seizure: an evidence based approach. *Postgrad Med J*. 2009;85(1010):667–673.
52. Martínez-Juarez IE, Moreno J, Ladino LD, et al. Diagnosis and treatment of non-triggered single epileptic seizures. *Rev Neurol*. 2016;63(4):165–175.
53. Nowacki TA, Jirsch JD. Evaluation of the first seizure patient: Key points in the history and physical examination. *Seizure*. 2017;49:54–63.
54. Cornes SB, Shih T. Evaluation of the Patient with Spells. *Continuum (Minneapolis)*. 2011;17(5):984–1009.
55. Jette N, Wiebe S. Initial Evaluation of the Patient with Suspected Epilepsy. *Neurol Clin*. 2016;34(2):339–350.
56. Wiebe S, Tellez-Zenteno JF, Shapiro M. An evidence-based approach to the first seizure. *Epilepsia*. 2008;49(Suppl 1):50–57.
57. Krumholz A, Wiebe S, Gronseth G, et al. Practice Parameter: evaluating an apparent unprovoked first seizure in adult (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. *Neurology*. 2007;69(21):1996–2007.
58. Jackson MJ. Concise guidance: diagnosis and management of the epilepsies in adults (NICE). *Clinical Medicine*. 2014;17(4):622–627.
59. Debicki DB. Electroencephalography after a single unprovoked seizure. *Seizure*. 2017;49:69–73.
60. Paliwal P, Wakerley BR, Yeo LL, et al. Early electroencephalography in patients with Emergency Room diagnoses of suspected new-onset seizures. Diagnostic yield and impact on clinical decision-making. *Seizure*. 2015;31:22–26.
61. Wyman AJ, Mayes BN, Hernandez-Nino J, et al. The First-Time Seizure Emergency Department Electroencephalogram Study. *Ann Emerg Med*. 2017;69(2):184–191.
62. Chen T, Si Y, Chen D, et al. The value of 24-hour video-EEG in evaluating recurrence risk following a first unprovoked seizure: A prospective study. *Seizure*. 2016;40:46–51.
63. Ho K, Lawn N, Bynevelt M, et al. Neuroimaging of first-ever-seizure: contribution of MRI if CT is normal. *Neurol Clin Practice*. 2013;3(5):398–403.
64. Hakami T, McIntosh A, Todaro M, et al. MRI-identified pathology in adults with new-onset seizures. *Neurology*. 2013;81(10):920–927.
65. Crocker CE. Role of the neuroimaging in first seizure diagnosis. *Seizure: Eur J Epilepsy*. 2017;49:74–78.
66. Crocker CE, Pohlmann-Eden B, Schmidt MH. Role of neuroimaging in first seizure diagnosis. *Seizure*. 2017;49:74–78.
67. Sampere AP, Villaverde FJ, Martínez-Menéndez B, et al. First seizure in adults: a prospective study from the emergency department. *Acta Neurol Scand*. 1992;86(2):134–138.
68. Zisimopoulou V, Mamali M, Katsavos S, et al. Cerebrospinal fluid analysis after unprovoked first seizure. *Funct Neurol*. 2016;31(2):191–197.
69. Chen DK, So YT, Fisher RS, et al. Use of serum prolactin in diagnosing epileptic seizures: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. *Neurology*. 2005;65(5):668–675.



70. Krishnanmurthy KB. In the Clinic: Epilepsy. *Annals of Internal Medicine*. 2016.
71. Hesdorffer DC, Benn EK, Cascino GD, et al. Is a first acute symptomatic seizure epilepsy? Mortality and risk for recurrent seizure. *Epilepsia*. 2009;50(5):1102–1108
72. Krumholz A, Wiebe S, Gronseth GS, et al. Evidence-based guideline: management of an unprovoked first seizure in adults: report of the guideline development subcommittee of the American Academy of Neurology and the American Epilepsy Society. *Neurology*. 2015;84(16):1705–1713.
73. Hart YM, Sander JW, Johnson AL, et al. National General Practice Study of Epilepsy recurrence after a first seizure. *Lancet*. 1990;336(8726):1271–1274.
74. Hauser WA, Rich SS, Lee JR, et al. Risk of recurrent seizures after two unprovoked seizures. *N Engl J Med*. 1998;338(7):429–434.
75. Kim LG, Johnson TL, Marson AG, et al. Prediction of risk of seizure recurrence after a single seizure and early epilepsy: further results from the MESS trial. *Lancet Neurol*. 2006;5(4):317–322.
76. Davenport RJ. Review: immediate vs deferred antiepileptics reduce recurrence at 1 to 2 years after an unprovoked first seizure. *Ann Intern Med*. 2015;163(6):JC8.
77. Randomized clinical trial on the efficacy of antiepileptic drugs in reducing the risk of relapse after a first unprovoked tonic-clonic seizure. First Seizure Trial Group (FIR.S.T. Group.). *Neurology*. 1993;43(3 pt 1):478–483.
78. Marson A, Jacoby A, Johnson A, et al. Immediate versus deferred antiepileptic drug treatment for early epilepsy and single seizures: a randomized controlled trial. *Lancet*. 2005;365(9476):2007–2013.
79. Chandra B. First seizure in adults: to treat or not to treat. *Clin Neurol Neurosurg*. 1992;94(Suppl):561–563.
80. Das CP, Sawhney IM, Lal V, et al. Risk of recurrence of seizures following single unprovoked idiopathic seizure. *Neurol India*. 2000;48(4):357–360.
81. Gilad R, Lampl Y, Gabbay U, et al. Early treatment of a single generalized tonic-clonic seizure to prevent recurrence. *Arch Neurol*. 1996;53(11):1149–1152.
82. Scottish Intercollegiate Guidelines Network (SIGN). *Diagnosis and management of epilepsy in adults*. Edinburgh: SIGN; 2015.
83. Glauser T, Ben-Manachem, Bourgeois B, et al. Update ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. *Epilepsia*. 2013;54(3):551–563.
84. Werhahn KJ, Trinka E, Dobesberger J, et al. A randomized, double-blind comparison of antiepileptic drug treatment in the elderly with new-onset focal epilepsy. *Epilepsia*. 2015;56(3):450–459.
85. Pohlmann-Eden B, Marson AG, Noack-Rink M, et al. Comparative effectiveness of levetiracetam, valproate and carbamazepine among elderly patients with newly diagnosed epilepsy. *BMC Neurol*. 2016;16(1):149–153.
86. Schmidt D, Sillanpää M. Stopping epilepsy treatment in seizure remission: Good or bad or both? *Seizure*. 2017;44:157–161.
87. Report of the Quality Standards Subcommittee of the American Academy of Neurology Practice parameter: a guideline for discontinuing antiepileptic drugs in seizure-free patients. *Neurology*. 1996;47(2):600–602.
88. Medical Research Council Antiepileptic Drug Withdrawal Study Group. Prognostic index for recurrence of seizures after remission of epilepsy. *BMJ*. 1993;306:1374–1378.
89. Medical Research Council Antiepileptic Drug Withdrawal Study Group. Randomised study of antiepileptic drug withdrawal in patient in remission. *Lancet*. 1991;337(8751):1175–1180.
90. Braun KP, Schmidt D. Stopping antiepileptic drugs in seizure-free patients. *Curr Opin Neurol*. 2014;27(2):219–226.
91. National Institute for Health and Clinical Excellence. *The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care : Pharmacological Update of Clinical Guideline 20*. NICE, 2012.
92. Rizvi S, Hernandez-Ronquillo L, Moien-Afshari F. Evaluating the single seizure clinic model. *J Neurol Sci*. 2016;367:203–210.
93. Legg KT, Newton M. Counselling adults who experience a first seizure. *Seizure*. 2017;49:64–68.
94. Beghi E, Leone M, Solari A. Mortality in Patients with a First Unprovoked Seizure. *Epilepsia*. 2005;46(Suppl 11):40–42.
95. Sander JW. Comorbidity and premature mortality in epilepsy. *Lancet*. 2013;382:1618–1619.
96. Lawn N, Chan J, Lee J, et al. Is the first seizure epilepsy – and when? *Epilepsia*. 2015;56(9):1425–1431.
97. Jackson A, Teo L, Seneviratne U. Challenges in the first seizure clinic for adult patients with epilepsy. *Epileptic Disor*. 2016;18(3):305–314.